{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-25-000026","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.597327+00:00","generated_at":"2026-05-24T02:32:28.820539+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Mineralys Therapeutics reports positive Phase 2 Advance-HTN trial results for lorundrostat in hypertension","bullets":["Lorundrostat 50 mg achieved a 7.9 mmHg placebo-adjusted reduction in 24-hour SBP at week 12 (p=0.001).","41% of lorundrostat patients achieved 24-hour SBP <125 mmHg at week 4 vs 18% on placebo (p<0.001).","Trial enrolled 53% Black and 40% female patients; safety showed low discontinuation and confirmed hyperkalemia rates of 2.1% and 3.2%.","Company plans to provide additional Phase 3 Launch-HTN data at an upcoming medical conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-25-000026","json":"https://secwatch.observer/filing/0001933414-25-000026.json","markdown":"https://secwatch.observer/filing/0001933414-25-000026.md","text":"https://secwatch.observer/filing/0001933414-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000026/0001933414-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000026/mlys-20250329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-24T02:32:28.820539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}